Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

Merck & Co halts development of potential COVID-19 drug MK-7110

Pharma company has abandoned drug due to technical, clinical and regulatory uncertainties

- PMLiVE

Making social sexy

By Amy Johnson

- PMLiVE

McCann Health UK appoints Jonathan Kukathasan as president

Kukathasan has spent over 15 years working at McCann Health

- PMLiVE

Indigo Medical joins imc group

The addition of Indigo Medical boosts imc group’s geographic footprint and capabilities

- PMLiVE

Saturnino Izquierdo takes on expanded role at McCann Health

Izquierdo has been appointed president, Europe and Latin America (LATAM) at the healthcare comms network

- PMLiVE

From if to how: when imagination and regulation work together

By Michael Bradley

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

GSK discontinues two feladilimab trials in head and neck cancer

Decision made after recommendation from Independent Data Monitoring Committee

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

Follow the user – democratising medical conference design

By Ute E Schmidt

- PMLiVE

UK trial evaluating mixed-vaccine regimens includes two more jabs

Results from the first stage of the Com-Cov trial are expected next month

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links